Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
AUPH Stock Forecast 2026-2027
$16.00
Current Price
$2.03B
Market Cap
Buy 4
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to AUPH Price Targets
+31.3%
To High Target of $21.00
+6.3%
To Median Target of $17.00
-6.3%
To Low Target of $15.00
AUPH Price Momentum
+1.4%
1 Week Change
+4.7%
1 Month Change
+96.6%
1 Year Change
+0.3%
Year-to-Date Change
-5.2%
From 52W High of $16.88
+119.6%
From 52W Low of $7.29
📊 TOP ANALYST CALLS
Did AUPH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Aurinia Pharma is one of their latest high-conviction picks.
Latest AUPH Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, AUPH has a bullish consensus with a median price target of $17.00 (ranging from $15.00 to $21.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $16.00, the median forecast implies a 6.3% upside. This outlook is supported by 4 Buy, 3 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Ed Arce at HC Wainwright & Co., suggesting a 6.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AUPH Analyst Ratings
4
Buy
3
Hold
0
Sell
AUPH Price Target Range
Low
$15.00
Average
$17.00
High
$21.00
Current: $16.00
Latest AUPH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AUPH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 3, 2025 | Leerink Partners | Joseph Schwartz | Market Perform | Downgrade | $16.00 |
| Nov 7, 2025 | Jefferies | Buy | Upgrade | $N/A | |
| Nov 5, 2025 | RBC Capital | Sector Perform | Downgrade | $N/A | |
| Aug 1, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Jul 30, 2025 | HC Wainwright & Co. | Arthur He | Buy | Assumes | $17.00 |
| Sep 16, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Sep 9, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Sep 6, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 1, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 23, 2024 | Cantor Fitzgerald | Overweight | Maintains | $N/A | |
| Feb 22, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 16, 2024 | RBC Capital | Outperform | Maintains | $N/A | |
| Sep 22, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 7, 2023 | HC Wainwright& Co. | Buy | Maintains | $N/A | |
| Aug 7, 2023 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $15.00 |
| Jul 6, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| May 3, 2023 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 23, 2023 | RBC Capital | Outperform | Reiterates | $N/A | |
| Jan 4, 2023 | RBC Capital | Outperform | Maintains | $N/A | |
| Nov 7, 2022 | HC Wainwright & Co. | Buy | Maintains | $N/A |
Aurinia Pharmaceuticals Inc (AUPH) Competitors
The following stocks are similar to Aurinia Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Aurinia Pharmaceuticals Inc (AUPH) Financial Data
Aurinia Pharmaceuticals Inc has a market capitalization of $2.03B with a P/E ratio of 7.3x. The company generates $298.30M in trailing twelve-month revenue with a 100.0% profit margin.
Revenue growth is +24.4% quarter-over-quarter, while maintaining an operating margin of +53.3% and return on equity of +65.0%.
Valuation Metrics
Market Cap
$2.03B
Enterprise Value
$1.72B
P/E Ratio
7.3x
PEG Ratio
0.1x
Price/Sales
6.8x
Growth & Margins
Revenue Growth (YoY)
+24.4%
Gross Margin
+91.6%
Operating Margin
+53.3%
Net Margin
+100.0%
EPS Growth
+47.2%
Financial Health
Cash/Price Ratio
+18.4%
Current Ratio
5.5x
Debt/Equity
12.1x
ROE
+65.0%
ROA
+13.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Aurinia Pharmaceuticals Inc (AUPH) Business Model
About Aurinia Pharmaceuticals Inc
What They Do
Develops therapies for autoimmune diseases.
Business Model
Aurinia Pharmaceuticals generates revenue primarily through the commercialization of its FDA-approved product, LUPKYNIS, which treats lupus nephritis. The company invests in research and development to advance its product pipeline, including partnerships with other pharmaceutical companies to enhance its offerings and market reach.
Additional Information
Founded in 1993 and based in Edmonton, Canada, Aurinia is focused on addressing significant unmet medical needs in the autoimmune disease sector. The company also works on innovative treatments and maintains collaborations to support its therapeutic initiatives, positioning itself as a key player in the biotechnology field.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
130
CEO
Mr. Peter S. Greenleaf M.B.A.
Country
Canada
IPO Year
2014
Website
www.auriniapharma.comAurinia Pharmaceuticals Inc (AUPH) Latest News & Analysis
Latest News
Quick Summary
Kevin Tang acquired 814,606 common shares for about $12.5 million at $15.29 each, representing 6.66% of his prior holdings, but retains zero direct ownership post-transaction.
Why It Matters
Kevin Tang's acquisition of shares indicates confidence in the company's value, potentially influencing market perception and stock price. The transaction size suggests significant investment activity.
Source: The Motley Fool
Market Sentiment:
Positive
LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death
12 days ago
Quick Summary
LUPKYNIS shows a statistically significant 53% reduction in the risk of renal-related events or death, according to a recent report.
Why It Matters
The 53% reduction in renal-related events or death for LUPKYNIS indicates strong efficacy, potentially boosting sales and market confidence, impacting stock performance positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Aurinia Pharmaceuticals (AUPH) reported 24% revenue growth and 48% net income growth in Q1 2026. It reaffirmed FY26 guidance for double-digit revenue gains. Tang Capital Management increased its stake above 10%.
Why It Matters
Aurinia Pharmaceuticals shows strong growth and positive financials, boosting investor confidence. Tang Capital’s increased stake indicates belief in AUPH's future potential and valuation.
Source: Seeking Alpha
Market Sentiment:
Positive
Aurinia Pharmaceuticals Inc. (AUPH) Shareholder/Analyst Call Prepared Remarks Transcript
12 days ago
Quick Summary
Aurinia Pharmaceuticals Inc. is hosting a shareholder and analyst call, where prepared remarks will be discussed. Details on financial performance and future outlook are expected.
Why It Matters
The shareholder/analyst call provides insights into Aurinia's performance, strategies, and future outlook, which can influence stock valuation and investment decisions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Aurinia Pharmaceuticals reported its financial results for Q1 2026 and provided an update on its recent business developments. Further details on performance and strategy may be available in the full report.
Why It Matters
Aurinia Pharmaceuticals' financial results and business updates signal performance trends and strategic direction, impacting investor sentiment and stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Aurinia Pharmaceuticals (AUPH) reported Q3 earnings of $0.25 per share, surpassing the Zacks Consensus Estimate of $0.18 and up from $0.16 per share year-over-year.
Why It Matters
Aurinia Pharmaceuticals' earnings beat expectations and increased year-over-year, indicating strong financial performance that could boost investor confidence and stock value.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About AUPH Stock
What is Aurinia Pharmaceuticals Inc's (AUPH) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, Aurinia Pharmaceuticals Inc (AUPH) has a median price target of $17.00. The highest price target is $21.00 and the lowest is $15.00.
Is AUPH stock a good investment in 2026?
According to current analyst ratings, AUPH has 4 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $16.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AUPH stock?
Wall Street analysts predict AUPH stock could reach $17.00 in the next 12 months. This represents a 6.3% increase from the current price of $16.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Aurinia Pharmaceuticals Inc's business model?
Aurinia Pharmaceuticals generates revenue primarily through the commercialization of its FDA-approved product, LUPKYNIS, which treats lupus nephritis. The company invests in research and development to advance its product pipeline, including partnerships with other pharmaceutical companies to enhance its offerings and market reach.
What is the highest forecasted price for AUPH Aurinia Pharmaceuticals Inc?
The highest price target for AUPH is $21.00 from at , which represents a 31.3% increase from the current price of $16.00.
What is the lowest forecasted price for AUPH Aurinia Pharmaceuticals Inc?
The lowest price target for AUPH is $15.00 from Ed Arce at HC Wainwright & Co., which represents a -6.3% decrease from the current price of $16.00.
What is the overall AUPH consensus from analysts for Aurinia Pharmaceuticals Inc?
The overall analyst consensus for AUPH is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $17.00.
How accurate are AUPH stock price projections?
Stock price projections, including those for Aurinia Pharmaceuticals Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 2:12 AM UTC